LLY FDA calendar & decision history Eli Lilly and Company · no upcoming catalyst on file · 6 past FDA decisions
FDA decision history (6) Jun 9, 2026✓ Approved EBGLYSS (lebrikizumab-lbkz) - Apr 1, 2026✓ Approved Foundayo (orforglipron) - (ATT Dec 3, 2025✓ Approved FDA decision Oct 27, 2025✓ Approved FDA decision Sep 25, 2025✓ Approved FDA decision Jan 15, 2025✓ Approved FDA decision See the full 2026 PDUFA calendar → This page aggregates LLY's FDA catalysts from pdufa.bio's own calendar and decision archive. Each item links to its source page. Facts and dates only; verify against primary FDA / SEC / company filings.
Not affiliated with or endorsed by the FDA. pdufa.bio is an independent service; "FDA", "PDUFA", and all company, drug, and ticker names are used descriptively and remain the property of their owners. Informational and educational only — not investment advice. Data and historical statistics only; no trade recommendations and no individual-drug approval probabilities. Verify every date and outcome against primary FDA / SEC / company filings. © 2026 pdufa.bio